Tweets by IDWeek 2023

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Back

332 Views

046. COVID-19: Special Populations: Thursday, 12:15 - 1:30 p.m.

Poster Session: COVID-19: Special Populations

(470) Clinical Effectiveness of The Monoclonal Antibody Combination Tixagevimab-Cilgavimab (T/C) as Pre-Exposure Prophylaxis (PReP) of COVID-19 among Patients (pts) with Moderate to Severe Immunocompromised (IC) Conditions across a Large U.S. Healthcare System: A Propensity Score-Matched Retrospective Cohort Study

Thursday, October 12, 2023

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

GH

Ghady Haidar, MD (he/him/his)

Assistant Professor of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States

Co-Author(s)

JL

Justin Ludwig, MA

Office of Quality and Clinical Research Innovation, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
DY

Donald M. Yealy, MD

University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
HC

Haley Camacho, PharmD candidate

Office of Quality and Clinical Research Innovation, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
TC

Tina Chinakarn, MPH

Office of Quality and Clinical Research Innovation, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
KK

Kevin Kip, PhD, FAAAS, FAHA

UPMC Health Services Division, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
SK

Stephen Koscumb, BA, BS

University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
OM

Oscar Marroquin, MD, MS

University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
TM

Tami Minnier, MSN, RN

University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
Graham M. Snyder, MD, SM (he/him/his)

Medical Director, Infection Prevention and Hospital Epidemiology
University of Pittsburgh
Pittsburgh, PA, United States
CW

Chelsea Woodworth, MS, RN, RHIA

University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Pittsburgh, Pennsylvania, United States
CF

Cátia Ferreira, PhD

Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA
Wilmington, Delaware, United States
LG

Lisa Glasser, MD

Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA
Wilmington, Delaware, United States
KH

Kathleen Heil, RN, BSN

Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA
Wilmington, Delaware, United States
AL

Andrew Lee, MSc

Medical and Payor Statistics, BioPharmaceutical Business Unit, AstraZeneca, Cambridge, UK
Cambridge, England, United Kingdom
CT

Carla Talarico, PhD, MPH

Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA
Gaithersburg, Maryland, United States
SV

Sudhir Venkatesan, MPH, PhD

Medical and Payer Evidence Statistics, BioPharmaceutical Medical, AstraZeneca, Cambridge, UK
Cambridge, England, United Kingdom
ST

Sylvia Taylor, PhD, MPH, MBA

Medical Evidence, Vaccines and Immune Therapies Unit, AstraZeneca, Cambridge, UK
Cambridge, England, United Kingdom
Erin K. McCreary, PharmD (she/her/hers)

Director of Infectious Diseases Improvement and Clinical Research Innovation
University of Pittsburgh Medical Center
Pittsburgh, PA, United States
JM

John W. Mellors, MD

Chief
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States